Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Common diabetes meds may lower lung cancer risk in COPD patients

NCT ID NCT07332156

First seen Jan 12, 2026 · Last updated Jun 23, 2026 · Updated 26 times

Summary

This study looked at medical records of over 21,000 adults with type 2 diabetes and COPD to see if a class of diabetes drugs called SGLT2 inhibitors is linked to a lower chance of developing lung cancer compared to older drugs called sulfonylureas. The researchers did not give any new treatments or ask participants to visit a clinic. Instead, they analyzed existing health data to find patterns. The goal is to learn whether SGLT2 inhibitors might offer an extra benefit beyond blood sugar control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SGLT2 inhibitors (a class of diabetes drugs)

What this could lead to

If SGLT2 inhibitors are linked to fewer lung cancer cases, this could point toward a new way to reduce cancer risk in high-risk patients.

What could go wrong

This is an observational study, not a controlled trial, so it can only show a link, not prove cause and effect. Other factors could explain any differences seen.

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset disease lung neoplasm type 2 diabetes mellitus lung cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.